EPA:GNFT Genfit Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Genfit S.A. Please log in to your account or sign up in order to add this asset to your watchlist. €3.10 +0.02 (+0.65%) (As of 07/4/2022 12:00 AM ET) Add Compare Share Today's Range€3.07▼€3.1550-Day Range€3.06▼€3.4852-Week Range N/AVolume80,987 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsHeadlines Genfit MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.0.22 out of 5 stars 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Genfit. Previous Next 0.0 Short Interest Short InterestThere is no current short interest data available for GNFT. Previous Next 0.0 Dividend Strength Dividend YieldGenfit does not currently pay a dividend.Dividend GrowthGenfit does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GNFT. Previous Next 1.1 News and Social Media Coverage News SentimentGenfit has a news sentiment score of 0.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Genfit insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive GNFT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genfit and its competitors with MarketBeat's FREE daily newsletter. Email Address About Genfit (EPA:GNFT) StockGenfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.Read More GNFT Stock News HeadlinesJune 14, 2022 | seekingalpha.comGNFT Genfit S.A.May 25, 2022 | finance.yahoo.comGENFIT: May 25, 2022 Combined Shareholders Meeting resultsMay 11, 2022 | seekingalpha.comGenfit reports Q1 resultsMay 11, 2022 | finance.yahoo.comGENFIT Reports First Quarter 2022 Financial Information (Unaudited financial information under IFRS)April 29, 2022 | finance.yahoo.comGENFIT Announces Publication of the 2021 Universal Registration Document; the 2021 Annual Report on Form 20-F and Availability of Preparatory Documents for the Annual Combined Shareholders Meeting on May 25, 2022April 14, 2022 | finance.yahoo.comWhat Makes GENFIT S.A. Unsponsored ADR (GNFT) a New Buy StockApril 11, 2022 | benzinga.comSVB Leerink Maintains Outperform on Genfit, Lowers Price Target to $10April 7, 2022 | seekingalpha.comGenfit GAAP EPS of €1.23, revenue of €85.58MApril 7, 2022 | nz.finance.yahoo.comGENFIT Reports Full-Year 2021 Financial Results and Provides Corporate UpdateJanuary 25, 2022 | nasdaq.comGENFIT S.A. American Depositary Shares (GNFT)January 11, 2022 | finance.yahoo.comCan GENFIT S.A. Unsponsored ADR (GNFT) Climb 79% to Reach the Level Wall Street Analysts Expect?December 17, 2021 | msn.comWhy Genfit Shares Are RisingDecember 17, 2021 | markets.businessinsider.comPre-market Movers: GNFT, ABEO, SPRB, IO, CERN…December 17, 2021 | msn.comThe Daily Biotech Pulse: Genfit Spikes On Liver Disease Drug Licensing Deal, Lyell Gets Nod For Solid Tumor Study, Decision-Day For Intra-Cellular, ArgenxJune 30, 2021 | finance.yahoo.comGENFIT: June 30, 2021 Annual Shareholders Meeting resultsJune 25, 2021 | benzinga.comGENFIT Highlights 2 Poster Presentations At 2 Scientific/Medical Events In Jun.June 23, 2021 | finance.yahoo.comGENFIT presents new NIS4® data in NASH at the International Liver Congress™ and the 81st Scientific Sessions of the American Diabetes AssociationApril 23, 2021 | benzinga.comGENFIT: Publication of the 2020 Universal...April 23, 2021 | finance.yahoo.comGENFIT: Publication of the 2020 Universal Registration Document and the 2020 Annual Report on Form 20-F; Annual Shareholders Meeting to take place on June 15, 2021April 1, 2021 | benzinga.comGenfit SA FY20 Sales €765K, Down From €31M YoYMarch 4, 2021 | finance.yahoo.comGENFIT appoints Jean-François Tiné to the Board of DirectorsFebruary 10, 2021 | finance.yahoo.comGENFIT: 2021 Financial CalendarFebruary 10, 2021 | finance.yahoo.comGenfit Pops 29% Pre-Market On ‘Positive’ Data From Liver Disease Therapy StudyJanuary 12, 2021 | finance.yahoo.comJanuary 13, 2021 Extraordinary Shareholders Meeting: Wide support for the resolutions submitted to the shareholders’ vote but quorum not met on first conveningJanuary 8, 2021 | finance.yahoo.comGENFIT Informs its Shareholders of Certain Procedures for the Extraordinary General Meeting of January 13, 2021See More Headlines Industry, Sector and Symbol Stock ExchangeEPA Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolEPA:GNFT CUSIPN/A CIKN/A Webwww.genfit.com Phone33 3 20 16 40 00FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Genfit Frequently Asked Questions How has Genfit's stock performed in 2022? Genfit's stock was trading at €4.32 on January 1st, 2022. Since then, GNFT shares have decreased by 28.2% and is now trading at €3.10. View the best growth stocks for 2022 here. Who are Genfit's key executives? Genfit's management team includes the following people: Mr. Jean-Francois Mouney, Co-Founder & Chairman (Age 67, Pay $332.42k)Mr. M. Pascal Prigent, Chief Exec. Officer (Age 54, Pay $503.74k)Prof. Bart Staels, Co-Founder & Chairman of the Scientific Advisory Board (Age 59)Mr. Thomas Baetz, Chief Financial Officer (Age 48)Mr. Pascal Caisey, Chief Operating Officer (Age 54)Dr. Dean W. Hum Ph.D., Chief Scientific Officer (Age 60)Mr. Laurent Lannoo, Corp. Sec. & Director of Legal Affairs (Age 52)Ms. Stefanie Magner, Chief Compliance Officer & VP of International Legal Affairs (Age 41)Ms. Emilie Desodt, Vice-Pres of HR (Age 39)Mr. Jean-Christophe Marcoux, Chief Strategy Officer (Age 45) Who are some of Genfit's key competitors? Some companies that are related to Genfit include 3SBio (TRSBF), 45525 (CUR.TO) (CUR), Abattis Bioceuticals (ATTBF), Abcam (ABCZF), Abzena (ABZA), Acrux (ACR), Actinogen Medical (ACW), AdAlta (1AD), Admedus (AHZ), Algernon Pharmaceuticals (AGNPF), ALK-Abelló A/S (AKBLF), Almirall (LBTSF), Alpha Tau Medical (DRTSW), Amplia Therapeutics (ATX) and Anagenics (AN1). View all of GNFT's competitors. What other stocks do shareholders of Genfit own? Based on aggregate information from My MarketBeat watchlists, some companies that other Genfit investors own include Alimentation Couche-Tard (ATD.B), Aecon Group (ARE), Algonquin Power & Utilities (AQN), Aptiv (APTV), American Tower (AMT), Advanced Micro Devices (AMD), Ambarella (AMBA), Albemarle (ALB), Adobe (ADBE) and Abbott Laboratories (ABT). What is Genfit's stock symbol? Genfit trades on the EPA under the ticker symbol "GNFT." What is Genfit's stock price today? One share of GNFT stock can currently be purchased for approximately €3.10. How many employees does Genfit have? Genfit employs 122 workers across the globe. How can I contact Genfit? Genfit's mailing address is Parc Eurasante 885 avenue Eugene Avinee, Loos, Hauts De France 59120. The official website for Genfit is www.genfit.com. The company can be reached via phone at 33 3 20 16 40 00. This page (EPA:GNFT) was last updated on 7/4/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
